SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is seeing a significant surge amid widespread rumors of an impending partnership with Novo Nordisk to sell obesity drugs on its platform, fueling intense short squeeze speculation due to high short interest and renewed optimism around its expanding peptide offerings.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is seeing immense upward pressure as escalating geopolitical tensions in the Middle East have effectively disrupted shipping through the critical Strait of Hormuz, causing widespread concerns about global oil supply. The community is actively discussing the potential for significantly higher crude prices, viewing the situation as a genuine supply 'plumbing break' rather than just a fleeting fear-driven rally.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is trending following news of an AI licensing partnership in Africa, sparking intense community discussion and predictions of a significant short squeeze driven by its notably low float and high cost to borrow.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Community excitement for Capricor Therapeutics is surging, driven by news of a key FDA official's departure, with many believing this removes a significant hurdle for Deramiocel's approval for Duchenne Muscular Dystrophy and could trigger a substantial short squeeze ahead of upcoming Phase 3 data presentation.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences (SLS) is gaining significant attention after its CEO highlighted potential "curative outcomes" for AML with GPS and SLS009, reinforcing expectations of extended patient survival in the REGAL trial and fueling widespread community speculation of an impending buyout and substantial short squeeze.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure (QURE) is trending as the community speculates that the impending departure of a key FDA official could lead to a more favorable regulatory path for its Huntington's disease gene therapy, AMT-130, after prior setbacks. This has sparked intense debate between those anticipating accelerated approval for gene therapies and bears who remain skeptical of the underlying drug data and the sustainability of the rally.

Seeker is building a decentralized mobile ecosystem designed to challenge entrenched mobile incumbents through its TEEPin network architecture and community governance. It aims to solve the pain points of centralized app store gatekeeping, lack of developer freedom, and restricted user access to crypto applications. The vision is to create a community-owned platform with decentralized governance, no gatekeepers, direct developer-user access, and TEEPin security architecture.

Seeker

SKR (Seeker), a Solana Smartphone Token, is trending following recent exchange listings and an incentive offering a discount for purchases made with SKR. The community is keenly focused on breaching a key price resistance level amid high trading volume, with anticipation for future catalysts balanced by warnings of potential sell-offs from early participants.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following a surprise partnership with Hims & Hers to sell obesity drugs, a move the community views as trapping shorts and signaling a major turnaround. This development, coupled with rapidly accelerating adoption of its oral Wegovy and a recent FDA crackdown on compounded GLP-1s, has many calling the stock a generational buying opportunity despite past competitive pressures.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network is trending as its community intensely debates the crypto's future, with many users expressing frustration over stalled KYC processes, unverified balances, and the lack of major exchange listings, while others remain steadfast in their long-term bullish outlook for the project.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as the community anticipates a more permissive regulatory environment for its gene therapies following the imminent departure of a prominent FDA official, an event coupled with the CEO's announced retirement sparking M&A speculation and excitement for upcoming pivotal clinical data.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Driving the Market Sentiment Around Dogwood Therapeutics Inc?

<ul class="summary-bullets"><li>Dogwood also reported a study dropout rate of 4.4%, which the company said is far below rates typically observed with other FDA approved chronic pain medicines.</li><li>The company expects to have top-line results from the trial available during the third quarter (Q3) of 2026.&nbsp;</li><li>Last month, Dogwood said that it has cash on hand of $10.1 million, providing operational runway only through the first quarter of 2026.</li></ul>Dogwood Therapeutics, Inc. (DWTX) said on Monday that patients with chemotherapy induced neuropathic pain (CINP) treated with its painkiller Halneuron demonstrated separation from placebo treated patients in terms of pain improvement over a four-week study. &nbsp;Shares of the company fell 22% at the time of writing and is now poised to log its worst day in over nine months as the update failed to boost investor sentiment.The separation in pain improvement was identified by an independent statistical review committee who reviewed patient treatment data from a mid-stage trial under which 97 patients have completed treatment so far. The company did not <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/12/22/3209363/0/en/Dogwood-Therapeutics-Announces-Positive-Interim-Phase-2b-Clinical-Trial-Results-in-Chemotherapy-Induced-Neuropathic-Pain.html">detail </a>the scale of pain improvement observed in the analysis.The company expects to have top-line results available during the third quarter (Q3) of 2026.Dogwood also reported a study dropout rate of 4.4%, which the company said is far below rates typically observed with other FDA approved chronic pain medicines.<h2 class="st-heading-2">Company Sounds Optimism</h2>According to Dogwood, current study patient enrollment trends are projected to provide statistical power of approximately 80% to 85% to detect a Halneuron treatment difference.“Extrapolation of the current Phase 2b study trends has the potential to represent the first statistically significant trial involving CINP patients under FDA chronic pain study guidance,” said CEO Greg Duncan.Halneuron is Dogwood’s lead product candidate and has been granted fast track designation from the FDA for the treatment of CINP. Last month, the company confirmed enrollment of 100 patients in the mid-stage study for Halneuron. The company is targeting enrolling 200 patients in the study in total.“We are hopeful that positive outcomes in this ongoing Phase 2b trial will set the stage for a Phase 3 registration program in CINP, providing a needed therapeutic option for this patient population of cancer survivors,” Chief Medical Officer Michael Gendreau said on Monday.<h2 class="st-heading-2">Limited Operational Runway</h2>Last month, Dogwood said that it has cash on hand of $10.1 million, providing operational runway only through the first quarter of 2026, before it can announce the results of the ongoing Halneuron trial. &nbsp;The company reported a third quarter basic and diluted net loss per share of $8.20, compared to an analyst estimate of a loss of $1.58 per share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around DWTX fell from ‘bullish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.A Stocktwits user now expects the stock to drop as low as $2.<stembedurl>https://www.stocktwits.com/hammerfall43/message/639878419</stembedurl><a href="https://stocktwits.com/symbol/DWTX">DWTX stock</a> has nearly doubled this year. &nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-hits-record-high-as-elon-musk-hints-at-fsd-launch-in-uae-next-month-amid-2018-pay-package-boost/cLeFNmTREMq">Tesla Stock Hits Record High As Elon Musk Hints At FSD Launch In UAE Next Month Amid 2018 Pay Package Boost</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

DWTX Stock Heads For Worst Day In 9 Months As Chemotherapy Pain Drug Interim Study Data Fails To Boost Investor Confidence

The company said that Halneuron demonstrated separation from placebo treated patients in terms of pain improvement but did not detail the scale of the said improvement. 

Equity

The company said that Halneuron demonstrated separation from placebo treated patients in terms of pain improvement but did not detail the scale of the said improvement. 


Dogwood Therapeutics, Inc. (DWTX) shares surged 50% in the pre-market session on Monday after the company announced that it has secured a license to develop Serpin Pharma’s intravenous formulation of SP16 to manage cancer-related pain (CRP).The royalty-free, global license will enable the company to develop SP16 for a broad range of chemotherapy-induced neuropathy symptoms as well.In return, Sepin Pharma and its designated affiliates will get 7.31% of the company’s common stock, on a fully diluted basis. This includes 382,034 shares of DWTX common stock and 179.1878 shares of a new series of non-voting convertible preferred stock, it said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DWTX">DWTX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.Dogwood <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/29/3157595/0/en/Dogwood-Therapeutics-Secures-Exclusive-Worldwide-Royalty-Free-License-to-Develop-and-Commercialize-SP16-as-a-Treatment-for-Cancer-Related-Pain-in-an-All-Stock-Transaction-Underscor.html">said</a> that SP16 has demonstrated both anti-inflammatory and neural repair activity. An early-stage trial of the intravenous formulation of SP16, fully funded by the National Cancer Institute, is slated to start patient enrollment in the first half of 2026.“The National Cancer Institute’s funding of the SP16 IV Phase 1b program obviates the need to use our existing capital in the near-term to advance SP16 into clinical development,” CEO Greg Duncan said.The company also noted that SP16 could complement its lead candidate Halneuron, which has demonstrated statistically significant and clinically meaningful pain reductions in general cancer pain, as well as chemotherapy-induced neuropathic pain, respectively.DWTX stock has more than tripled this year and risen by about 79% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug 

In return for the license, Sepin Pharma and its designated affiliates will get 7.31% of Dogwood’s common stock, on a fully diluted basis.

Shares of Dogwood Therapeutics Inc. rose over 18% in premarket trading Friday, following a jaw-dropping 370% surge in the previous session.&nbsp;Trading volume was over 62 times the daily average, with retail investors on Stocktwits making it the most discussed biotech stock before the bell.While there was no fresh news on Friday, the rally appears to stem from an&nbsp;earlier announcement.&nbsp;Dogwood disclosed on Tuesday that it plans to begin dosing the first patient in its Phase 2b HALT-CINP trial in the first quarter of 2025.&nbsp;The trial evaluates Halneuron, a non-opioid therapy aimed at alleviating neuropathic pain linked to chemotherapy.The company’s focus on pain and fatigue-related disorders has generated excitement, bolstered by its non-opioid analgesic and antiviral platforms.&nbsp;Retail attention on Stocktwits has skyrocketed. The stock saw an 8,500% jump in message volume on Thursday, with&nbsp;its retail&nbsp;following increasing by 18% in a single day.&nbsp;<stembedurl>https://stocktwits.com/OFFC18/message/601301523</stembedurl><stembedurl>https://stocktwits.com/BullsEye2000/message/601306713</stembedurl>Dogwood stock is up over 400% year-to-date and has lost 95% over the past 12 months.&nbsp;The massive surge has reignited attention, although its low liquidity and early-stage pipeline make it a volatile bet.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Dogwood Therapeutics Becomes Most Actively Discussed Biotech Stock Among Retail Traders After Stunning 370% Surge

The company’s focus on pain and fatigue-related disorders has generated excitement, bolstered by its non-opioid analgesic and antiviral platforms.

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.86	--	--	N/A
Q3 '25	-$1.16	-$8.20	-606.90%	MISSED
Q2 '25	-$0.79	-$1.99	-151.90%	MISSED
Q1 '25	-$2.09	-$8.45	-304.31%	MISSED
Q4 '24	-$1.41	-$6.29	-344.52%	MISSED

DWTX
Dogwood Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest DWTX News

DWTXDogwood Therapeutics Inc.